Loading…
Malignant rhabdoid tumours of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: A report of the SIOP renal tumour study group
Background Survival data of malignant rhabdoid tumour of the kidney (MRTK) registered in SIOP trials, advocating preoperative chemotherapy, are not available. Aim To evaluate characteristics, response and survival of MRTK patients registered in recent SIOP protocols. Methods An evaluation of all MRT...
Saved in:
| Published in: | Pediatric blood & cancer 2011-05, Vol.56 (5), p.733-737 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4502-52a5bea7ad0d6dba59e28f869fdeef3ec1261483ad2fcb6b1bbb40c7b433023f3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4502-52a5bea7ad0d6dba59e28f869fdeef3ec1261483ad2fcb6b1bbb40c7b433023f3 |
| container_end_page | 737 |
| container_issue | 5 |
| container_start_page | 733 |
| container_title | Pediatric blood & cancer |
| container_volume | 56 |
| creator | van den Heuvel-Eibrink, Marry M. van Tinteren, Harm Rehorst, Harriet Coulombe, Aurore Patte, Catharine de Camargo, Beatriz de Kraker, Jan Leuschner, Ivo Lugtenberg, Rieneke Pritchard-Jones, Kathy Sandstedt, Bengt Spreafico, Filippo Graf, Norbert Vujanic, Gordan M. |
| description | Background
Survival data of malignant rhabdoid tumour of the kidney (MRTK) registered in SIOP trials, advocating preoperative chemotherapy, are not available. Aim To evaluate characteristics, response and survival of MRTK patients registered in recent SIOP protocols.
Methods
An evaluation of all MRTK patients treated from 1993 to 2005 (SIOP trials 93‐01 and 2001) was performed. Data were obtained from study specific case record forms and entered centrally in a database.
Results
Hundred and seven patients were identified (57 male), with a median age at diagnosis of 13 months (interquartile range 6–27 months), and a median follow‐up time of 60 months. Left and right kidneys were equally affected. Tumour stage distribution was stage I (6%), stage II (22%), stage III (43%), stage IV (22%) and stage V (3%). Stage IV patients included 17 with pulmonary metastasis (8 lung‐only) and 12 with multiple organ metastases (bone, brain and liver). Primary surgery was the upfront treatment approach in 22/107 patients (21%), by which 19 patients reached a complete remission (CR). Median difference in tumour volume before and after preoperative chemotherapy was 69 ml (interquartile range: 4.5–158.0, P |
| doi_str_mv | 10.1002/pbc.22922 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_545815</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>855201621</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4502-52a5bea7ad0d6dba59e28f869fdeef3ec1261483ad2fcb6b1bbb40c7b433023f3</originalsourceid><addsrcrecordid>eNp1kVtv0zAYhi3ExEbHBX8A-Q4mkc2HOAfuRgVjardVMDSJG8uOv3ShSRzsRKN_hN-Lu6bd1a580PO8n-wXobeUnFJC2Fmni1PGcsZeoCMqYhEJQtOX-z3JD9Fr738HNCEie4UOGeUpiUl8hP5dqbpatqrtsbtX2tjK4H5o7OA8tiXu7wGvKtPCGn-4-n478ycfsYNl5XtwYLBtw6mAIP-4vFngztneFrb2uHS2wTTPOe4tZoSIT_g8oJ11_S720XDQqnociH0_mDVeOjt0x-igVLWHN-M6QT-_frmdfovmNxeX0_N5VMSCsEgwJTSoVBliEqOVyIFlZZbkpQEoORSUJTTOuDKsLHSiqdY6JkWqY84J4yWfoGib6x-gG7TsXNUot5ZWVXK8WoUdyPCTGRWBz5_lw-vNk7QTKWM0ianYuO-3bgD_DOB72VS-gLpWLdjBy0wIRmgSupmgky1ZOOu9g3I_hxK5aVyGxuVj44F9N6YOugGzJ3cVB-BsCzxUNayfT5KLz9Nd5Pgpm5r_7g3lVjJJeSrk3fWFnN3l8zn7tZAz_h_GScWY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>855201621</pqid></control><display><type>article</type><title>Malignant rhabdoid tumours of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: A report of the SIOP renal tumour study group</title><source>Wiley</source><creator>van den Heuvel-Eibrink, Marry M. ; van Tinteren, Harm ; Rehorst, Harriet ; Coulombe, Aurore ; Patte, Catharine ; de Camargo, Beatriz ; de Kraker, Jan ; Leuschner, Ivo ; Lugtenberg, Rieneke ; Pritchard-Jones, Kathy ; Sandstedt, Bengt ; Spreafico, Filippo ; Graf, Norbert ; Vujanic, Gordan M.</creator><creatorcontrib>van den Heuvel-Eibrink, Marry M. ; van Tinteren, Harm ; Rehorst, Harriet ; Coulombe, Aurore ; Patte, Catharine ; de Camargo, Beatriz ; de Kraker, Jan ; Leuschner, Ivo ; Lugtenberg, Rieneke ; Pritchard-Jones, Kathy ; Sandstedt, Bengt ; Spreafico, Filippo ; Graf, Norbert ; Vujanic, Gordan M.</creatorcontrib><description>Background
Survival data of malignant rhabdoid tumour of the kidney (MRTK) registered in SIOP trials, advocating preoperative chemotherapy, are not available. Aim To evaluate characteristics, response and survival of MRTK patients registered in recent SIOP protocols.
Methods
An evaluation of all MRTK patients treated from 1993 to 2005 (SIOP trials 93‐01 and 2001) was performed. Data were obtained from study specific case record forms and entered centrally in a database.
Results
Hundred and seven patients were identified (57 male), with a median age at diagnosis of 13 months (interquartile range 6–27 months), and a median follow‐up time of 60 months. Left and right kidneys were equally affected. Tumour stage distribution was stage I (6%), stage II (22%), stage III (43%), stage IV (22%) and stage V (3%). Stage IV patients included 17 with pulmonary metastasis (8 lung‐only) and 12 with multiple organ metastases (bone, brain and liver). Primary surgery was the upfront treatment approach in 22/107 patients (21%), by which 19 patients reached a complete remission (CR). Median difference in tumour volume before and after preoperative chemotherapy was 69 ml (interquartile range: 4.5–158.0, P < 0.0001), indicating marked chemosensitivity. The 5‐year event‐free survival (EFS) of the total group was 22% (95% CI: 15–33) and overall survival 26% (95% CI: 18–37). Most events (86%) occurred within the first 2 years after diagnosis. Younger age at diagnosis was an important adverse prognostic factors for survival. In contrast, tumour volume at diagnosis, nor volume reduction was associated with outcome.
Conclusion
MRTK has a poor outcome especially in young and advanced‐stage disease patients. Neither tumour volume at diagnosis, nor pre‐operative chemosensitivity are prognostic factors for survival. Pediatr Blood Cancer 2011;56:733–737. © 2010 Wiley‐Liss, Inc.</description><identifier>ISSN: 1545-5009</identifier><identifier>ISSN: 1545-5017</identifier><identifier>EISSN: 1545-5017</identifier><identifier>DOI: 10.1002/pbc.22922</identifier><identifier>PMID: 21370404</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Child, Preschool ; children ; Combined Modality Therapy ; Dactinomycin - therapeutic use ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Infant ; kidney ; Kidney Neoplasms - drug therapy ; Kidney Neoplasms - mortality ; Kidney Neoplasms - pathology ; Male ; Medicin och hälsovetenskap ; Neoplasm Metastasis ; Neoplasm Staging ; Registries ; Rhabdoid Tumor - drug therapy ; Rhabdoid Tumor - mortality ; Rhabdoid Tumor - pathology ; rhabdoid tumour ; Survival Rate ; Treatment Outcome ; Vincristine - therapeutic use</subject><ispartof>Pediatric blood & cancer, 2011-05, Vol.56 (5), p.733-737</ispartof><rights>Copyright © 2010 Wiley‐Liss, Inc.</rights><rights>Copyright © 2010 Wiley-Liss, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4502-52a5bea7ad0d6dba59e28f869fdeef3ec1261483ad2fcb6b1bbb40c7b433023f3</citedby><cites>FETCH-LOGICAL-c4502-52a5bea7ad0d6dba59e28f869fdeef3ec1261483ad2fcb6b1bbb40c7b433023f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21370404$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:122164155$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>van den Heuvel-Eibrink, Marry M.</creatorcontrib><creatorcontrib>van Tinteren, Harm</creatorcontrib><creatorcontrib>Rehorst, Harriet</creatorcontrib><creatorcontrib>Coulombe, Aurore</creatorcontrib><creatorcontrib>Patte, Catharine</creatorcontrib><creatorcontrib>de Camargo, Beatriz</creatorcontrib><creatorcontrib>de Kraker, Jan</creatorcontrib><creatorcontrib>Leuschner, Ivo</creatorcontrib><creatorcontrib>Lugtenberg, Rieneke</creatorcontrib><creatorcontrib>Pritchard-Jones, Kathy</creatorcontrib><creatorcontrib>Sandstedt, Bengt</creatorcontrib><creatorcontrib>Spreafico, Filippo</creatorcontrib><creatorcontrib>Graf, Norbert</creatorcontrib><creatorcontrib>Vujanic, Gordan M.</creatorcontrib><title>Malignant rhabdoid tumours of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: A report of the SIOP renal tumour study group</title><title>Pediatric blood & cancer</title><addtitle>Pediatr. Blood Cancer</addtitle><description>Background
Survival data of malignant rhabdoid tumour of the kidney (MRTK) registered in SIOP trials, advocating preoperative chemotherapy, are not available. Aim To evaluate characteristics, response and survival of MRTK patients registered in recent SIOP protocols.
Methods
An evaluation of all MRTK patients treated from 1993 to 2005 (SIOP trials 93‐01 and 2001) was performed. Data were obtained from study specific case record forms and entered centrally in a database.
Results
Hundred and seven patients were identified (57 male), with a median age at diagnosis of 13 months (interquartile range 6–27 months), and a median follow‐up time of 60 months. Left and right kidneys were equally affected. Tumour stage distribution was stage I (6%), stage II (22%), stage III (43%), stage IV (22%) and stage V (3%). Stage IV patients included 17 with pulmonary metastasis (8 lung‐only) and 12 with multiple organ metastases (bone, brain and liver). Primary surgery was the upfront treatment approach in 22/107 patients (21%), by which 19 patients reached a complete remission (CR). Median difference in tumour volume before and after preoperative chemotherapy was 69 ml (interquartile range: 4.5–158.0, P < 0.0001), indicating marked chemosensitivity. The 5‐year event‐free survival (EFS) of the total group was 22% (95% CI: 15–33) and overall survival 26% (95% CI: 18–37). Most events (86%) occurred within the first 2 years after diagnosis. Younger age at diagnosis was an important adverse prognostic factors for survival. In contrast, tumour volume at diagnosis, nor volume reduction was associated with outcome.
Conclusion
MRTK has a poor outcome especially in young and advanced‐stage disease patients. Neither tumour volume at diagnosis, nor pre‐operative chemosensitivity are prognostic factors for survival. Pediatr Blood Cancer 2011;56:733–737. © 2010 Wiley‐Liss, Inc.</description><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Child, Preschool</subject><subject>children</subject><subject>Combined Modality Therapy</subject><subject>Dactinomycin - therapeutic use</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Infant</subject><subject>kidney</subject><subject>Kidney Neoplasms - drug therapy</subject><subject>Kidney Neoplasms - mortality</subject><subject>Kidney Neoplasms - pathology</subject><subject>Male</subject><subject>Medicin och hälsovetenskap</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasm Staging</subject><subject>Registries</subject><subject>Rhabdoid Tumor - drug therapy</subject><subject>Rhabdoid Tumor - mortality</subject><subject>Rhabdoid Tumor - pathology</subject><subject>rhabdoid tumour</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><subject>Vincristine - therapeutic use</subject><issn>1545-5009</issn><issn>1545-5017</issn><issn>1545-5017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNp1kVtv0zAYhi3ExEbHBX8A-Q4mkc2HOAfuRgVjardVMDSJG8uOv3ShSRzsRKN_hN-Lu6bd1a580PO8n-wXobeUnFJC2Fmni1PGcsZeoCMqYhEJQtOX-z3JD9Fr738HNCEie4UOGeUpiUl8hP5dqbpatqrtsbtX2tjK4H5o7OA8tiXu7wGvKtPCGn-4-n478ycfsYNl5XtwYLBtw6mAIP-4vFngztneFrb2uHS2wTTPOe4tZoSIT_g8oJ11_S720XDQqnociH0_mDVeOjt0x-igVLWHN-M6QT-_frmdfovmNxeX0_N5VMSCsEgwJTSoVBliEqOVyIFlZZbkpQEoORSUJTTOuDKsLHSiqdY6JkWqY84J4yWfoGib6x-gG7TsXNUot5ZWVXK8WoUdyPCTGRWBz5_lw-vNk7QTKWM0ianYuO-3bgD_DOB72VS-gLpWLdjBy0wIRmgSupmgky1ZOOu9g3I_hxK5aVyGxuVj44F9N6YOugGzJ3cVB-BsCzxUNayfT5KLz9Nd5Pgpm5r_7g3lVjJJeSrk3fWFnN3l8zn7tZAz_h_GScWY</recordid><startdate>201105</startdate><enddate>201105</enddate><creator>van den Heuvel-Eibrink, Marry M.</creator><creator>van Tinteren, Harm</creator><creator>Rehorst, Harriet</creator><creator>Coulombe, Aurore</creator><creator>Patte, Catharine</creator><creator>de Camargo, Beatriz</creator><creator>de Kraker, Jan</creator><creator>Leuschner, Ivo</creator><creator>Lugtenberg, Rieneke</creator><creator>Pritchard-Jones, Kathy</creator><creator>Sandstedt, Bengt</creator><creator>Spreafico, Filippo</creator><creator>Graf, Norbert</creator><creator>Vujanic, Gordan M.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope></search><sort><creationdate>201105</creationdate><title>Malignant rhabdoid tumours of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: A report of the SIOP renal tumour study group</title><author>van den Heuvel-Eibrink, Marry M. ; van Tinteren, Harm ; Rehorst, Harriet ; Coulombe, Aurore ; Patte, Catharine ; de Camargo, Beatriz ; de Kraker, Jan ; Leuschner, Ivo ; Lugtenberg, Rieneke ; Pritchard-Jones, Kathy ; Sandstedt, Bengt ; Spreafico, Filippo ; Graf, Norbert ; Vujanic, Gordan M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4502-52a5bea7ad0d6dba59e28f869fdeef3ec1261483ad2fcb6b1bbb40c7b433023f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Child, Preschool</topic><topic>children</topic><topic>Combined Modality Therapy</topic><topic>Dactinomycin - therapeutic use</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Infant</topic><topic>kidney</topic><topic>Kidney Neoplasms - drug therapy</topic><topic>Kidney Neoplasms - mortality</topic><topic>Kidney Neoplasms - pathology</topic><topic>Male</topic><topic>Medicin och hälsovetenskap</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasm Staging</topic><topic>Registries</topic><topic>Rhabdoid Tumor - drug therapy</topic><topic>Rhabdoid Tumor - mortality</topic><topic>Rhabdoid Tumor - pathology</topic><topic>rhabdoid tumour</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><topic>Vincristine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van den Heuvel-Eibrink, Marry M.</creatorcontrib><creatorcontrib>van Tinteren, Harm</creatorcontrib><creatorcontrib>Rehorst, Harriet</creatorcontrib><creatorcontrib>Coulombe, Aurore</creatorcontrib><creatorcontrib>Patte, Catharine</creatorcontrib><creatorcontrib>de Camargo, Beatriz</creatorcontrib><creatorcontrib>de Kraker, Jan</creatorcontrib><creatorcontrib>Leuschner, Ivo</creatorcontrib><creatorcontrib>Lugtenberg, Rieneke</creatorcontrib><creatorcontrib>Pritchard-Jones, Kathy</creatorcontrib><creatorcontrib>Sandstedt, Bengt</creatorcontrib><creatorcontrib>Spreafico, Filippo</creatorcontrib><creatorcontrib>Graf, Norbert</creatorcontrib><creatorcontrib>Vujanic, Gordan M.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>Pediatric blood & cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van den Heuvel-Eibrink, Marry M.</au><au>van Tinteren, Harm</au><au>Rehorst, Harriet</au><au>Coulombe, Aurore</au><au>Patte, Catharine</au><au>de Camargo, Beatriz</au><au>de Kraker, Jan</au><au>Leuschner, Ivo</au><au>Lugtenberg, Rieneke</au><au>Pritchard-Jones, Kathy</au><au>Sandstedt, Bengt</au><au>Spreafico, Filippo</au><au>Graf, Norbert</au><au>Vujanic, Gordan M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Malignant rhabdoid tumours of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: A report of the SIOP renal tumour study group</atitle><jtitle>Pediatric blood & cancer</jtitle><addtitle>Pediatr. Blood Cancer</addtitle><date>2011-05</date><risdate>2011</risdate><volume>56</volume><issue>5</issue><spage>733</spage><epage>737</epage><pages>733-737</pages><issn>1545-5009</issn><issn>1545-5017</issn><eissn>1545-5017</eissn><abstract>Background
Survival data of malignant rhabdoid tumour of the kidney (MRTK) registered in SIOP trials, advocating preoperative chemotherapy, are not available. Aim To evaluate characteristics, response and survival of MRTK patients registered in recent SIOP protocols.
Methods
An evaluation of all MRTK patients treated from 1993 to 2005 (SIOP trials 93‐01 and 2001) was performed. Data were obtained from study specific case record forms and entered centrally in a database.
Results
Hundred and seven patients were identified (57 male), with a median age at diagnosis of 13 months (interquartile range 6–27 months), and a median follow‐up time of 60 months. Left and right kidneys were equally affected. Tumour stage distribution was stage I (6%), stage II (22%), stage III (43%), stage IV (22%) and stage V (3%). Stage IV patients included 17 with pulmonary metastasis (8 lung‐only) and 12 with multiple organ metastases (bone, brain and liver). Primary surgery was the upfront treatment approach in 22/107 patients (21%), by which 19 patients reached a complete remission (CR). Median difference in tumour volume before and after preoperative chemotherapy was 69 ml (interquartile range: 4.5–158.0, P < 0.0001), indicating marked chemosensitivity. The 5‐year event‐free survival (EFS) of the total group was 22% (95% CI: 15–33) and overall survival 26% (95% CI: 18–37). Most events (86%) occurred within the first 2 years after diagnosis. Younger age at diagnosis was an important adverse prognostic factors for survival. In contrast, tumour volume at diagnosis, nor volume reduction was associated with outcome.
Conclusion
MRTK has a poor outcome especially in young and advanced‐stage disease patients. Neither tumour volume at diagnosis, nor pre‐operative chemosensitivity are prognostic factors for survival. Pediatr Blood Cancer 2011;56:733–737. © 2010 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>21370404</pmid><doi>10.1002/pbc.22922</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1545-5009 |
| ispartof | Pediatric blood & cancer, 2011-05, Vol.56 (5), p.733-737 |
| issn | 1545-5009 1545-5017 1545-5017 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_545815 |
| source | Wiley |
| subjects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use Child, Preschool children Combined Modality Therapy Dactinomycin - therapeutic use Disease-Free Survival Female Follow-Up Studies Humans Infant kidney Kidney Neoplasms - drug therapy Kidney Neoplasms - mortality Kidney Neoplasms - pathology Male Medicin och hälsovetenskap Neoplasm Metastasis Neoplasm Staging Registries Rhabdoid Tumor - drug therapy Rhabdoid Tumor - mortality Rhabdoid Tumor - pathology rhabdoid tumour Survival Rate Treatment Outcome Vincristine - therapeutic use |
| title | Malignant rhabdoid tumours of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: A report of the SIOP renal tumour study group |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T00%3A30%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Malignant%20rhabdoid%20tumours%20of%20the%20kidney%20(MRTKs),%20registered%20on%20recent%20SIOP%20protocols%20from%201993%20to%202005:%20A%20report%20of%20the%20SIOP%20renal%20tumour%20study%20group&rft.jtitle=Pediatric%20blood%20&%20cancer&rft.au=van%20den%20Heuvel-Eibrink,%20Marry%20M.&rft.date=2011-05&rft.volume=56&rft.issue=5&rft.spage=733&rft.epage=737&rft.pages=733-737&rft.issn=1545-5009&rft.eissn=1545-5017&rft_id=info:doi/10.1002/pbc.22922&rft_dat=%3Cproquest_swepu%3E855201621%3C/proquest_swepu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4502-52a5bea7ad0d6dba59e28f869fdeef3ec1261483ad2fcb6b1bbb40c7b433023f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=855201621&rft_id=info:pmid/21370404&rfr_iscdi=true |